What is the status of BioCryst Pharmaceuticals' Orladeyo patent infringement lawsuit?
BioCryst Pharmaceuticals has filed a patent infringement lawsuit concerning its hereditary angioedema (HAE) drug, Orladeyo (berotralstat) [1]. The lawsuit was initiated in the U.S. District Court for the District of Delaware against an unnamed defendant [1].
Why is BioCryst suing over Orladeyo patents?
The lawsuit alleges that the defendant has infringed upon BioCryst's U.S. Patent No. 11,780,178, which pertains to methods of treating HAE with berotralstat [1]. BioCryst is seeking to prevent the defendant from continuing these alleged infringing activities [1].
When is the patent at the center of the lawsuit set to expire?
The patent in question, U.S. Patent No. 11,780,178, is slated to expire in 2042 [1]. This patent covers specific methods for using berotralstat to treat HAE.
Are there other patents protecting Orladeyo?
Beyond the '178 patent, BioCryst holds other patents related to berotralstat and its use in treating HAE. The company's intellectual property portfolio for Orladeyo includes a combination of formulation, method of use, and composition of matter patents [2]. DrugPatentWatch.com provides further details on these patents and their expiration dates [2].
What are the implications of this lawsuit for Orladeyo's market exclusivity?
If BioCryst is successful in its infringement lawsuit, it could prevent the unauthorized commercialization of competing products that utilize the patented methods [1]. This would help preserve Orladeyo's market exclusivity and protect BioCryst's investment in the drug's development and commercialization.
What are the potential outcomes of the Orladeyo patent lawsuit?
The lawsuit could result in a court injunction prohibiting the defendant from infringing the patent [1]. BioCryst may also seek monetary damages if infringement is proven [1]. The defendant, in turn, could challenge the validity or enforceability of the patent.
What is hereditary angioedema (HAE)?
Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of severe swelling in various parts of the body, including the limbs, face, and airway [3]. These attacks can be painful and potentially life-threatening if they affect the airway [3].
How does Orladeyo (berotralstat) work to treat HAE?
Orladeyo is a plasma kallikrein inhibitor [3]. By inhibiting plasma kallikrein, it helps to break the cycle that leads to HAE attacks [3].
What are the patient concerns surrounding Orladeyo?
Patients are generally concerned about the efficacy and safety of HAE treatments, as well as accessibility and cost [4]. For Orladeyo, as with any medication, patient perspectives would include managing side effects and understanding its long-term benefits [4].
How does Orladeyo compare to other HAE treatments?
Orladeyo is an oral, once-daily therapy [3]. Other HAE treatments include injectable therapies (subcutaneous or intravenous) and are often administered on demand or prophylactically [5]. The choice of treatment often depends on individual patient needs, attack frequency, and administration preferences.
Sources:
[1] https://www.drugpatentwatch.com/news/biocryst-pharmaceuticals-initiates-patent-infringement-lawsuit-for-orladeyo
[2] https://www.drugpatentwatch.com/drug/berotralstat
[3] https://www.drugpatentwatch.com/drug/berotralstat/overview
[4] https://www.drugpatentwatch.com/patient-concerns
[5] https://www.drugpatentwatch.com/drug/berotralstat/alternatives